Forty Seven Inc. announced preclinical proof-of-concept data for its novel all antibody conditioning regimen. This announcement caused the stock price climbing. Until Monday, December 9, Forty Seven Inc. (FTSV) shares were traded at $14,44. Two…
Forty Seven Inc. announced preclinical proof-of-concept data for its novel all antibody conditioning regimen. This announcement caused the stock price climbing. Until Monday, December 9, Forty Seven Inc. (FTSV) shares were traded at $14,44. Two…